|
Studies Link Gene Mutation to Parkinson's Disease
Last Updated: 2005-01-18 8:35:37 -0400 (Reuters Health)
By Patricia Reaney
NEW YORK (Reuters Health) - Three teams of scientists have identified a genetic
mutation that is linked to about 5 percent of inherited cases of Parkinson's
disease.
The fault on the recently discovered LRRK2 gene is one of five genetic
defects linked to the progressive nervous system disorder and could lead to
improved diagnosis and the development of a genetic test.
"Our results suggest that the mutation we have studied is the most common
cause of Parkinson's disease identified to date," said Dr Tatiana Foroud, an
associate professor at Indiana University School of Medicine in
Indianapolis.
The research is one of three studies by scientists in Britain, the
Netherlands and the United States who identified the LRRK2 gene mutation.
Their findings are published online by The Lancet medical journal Tuesday.
Foroud and her colleagues pinpointed the defect by analyzing the genetic
background of 767 Parkinson's disease patients from 358 different families.
Dr Nicholas Wood, of the National Hospital for Neurology and Neurosurgery in
London, and his team focused on patients without a family history of the
illness. They found it was also implicated in sporadic cases.
Dr Vincenzo Bonifati of Erasmus Medical Center in Rotterdam in the
Netherlands studied 61 families with two or more members with the illness.
"We found there is a novel mutation which is common in these families,"
Bonifati said in an interview. "The other groups in the UK and the US found
the same mutation independently."
Parkinson's is a chronic, irreversible neurodegenerative disease that
affects 1 percent of people over the age of 65 worldwide. Actor Michael J
Fox and boxing legend Mohammed Ali are sufferers.
The illness occurs when brain cells that produce a chemical called dopamine
malfunction and die. Symptoms include tremors, stiffness, slow movement and
poor coordination and balance.
"It is very important for scientists to establish novel (therapeutic)
approaches based on the function of this gene," said Bonifati.
"The main challenge is now to try and understand how this and other
Parkinson disease-associated LRRK2 mutations lead to neurodegenerative
disease, in order to design novel therapeutic and preventive strategies," he
added.
SOURCE: Lancet, online January 18, 2005.
Copyright © 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
|
